Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CADI-R101
- Development stage
- Preclinical
- Lead developer
- Bio-Modeling Systems
- Modality
- Small Molecules
01
Overview
CADI-R101 is a therapeutic program in the discovery stage, developed by Bio-Modeling Systems (BMSystems) for applications in infection and immunology. The program was identified using the company's proprietary CADI™ (Computer-Aided Design for In silico discovery) platform, which utilizes non-mathematical heuristic modeling to simulate complex biological systems and identify novel therapeutic interventions. As a "High Interest Program" within the BMSystems pipeline, CADI-R101 represents an early-stage effort to address unmet needs in infectious diseases and immune system dysfunction through predictive biological modeling.
Beyond the preview
Go deeper on CADI-R101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CADI-R101.